Leica Biosystems Announces Availability of Aperio HALO AP Image Management System in Canada
Vista, CA — May 28, 2026 Leica Biosystems, a Danaher company and global leader in anatomic and digital pathology solutions, today announced the availability of the Aperio HALO AP image management system (IMS) in Canada. The platform is designed to streamline digital pathology workflows by unifying whole slide images and case data within a single, intuitive environment.
Aperio HALO AP IMS, developed in partnership with Indica Labs, provides a comprehensive suite of tools for routine clinical practice, including on screen diagnosis, multidisciplinary team meetings, second opinions, and consultations, within a scalable ecosystem purpose built for pathology.
Key capabilities include:
- Centralized management of whole slide images and associated case data for routine on-screen diagnostics
- An intuitive, ergonomic user interface designed for efficient navigation and review
- Interoperability with scanners and laboratory information systems to support scalable workflows
- A French language user interface for use in Canada
“Expanding availability of Aperio HALO AP IMS in Canada reflects our commitment to enabling more connected and efficient digital pathology workflows,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “By unifying image and case data within a single platform, we are helping laboratories improve collaboration, streamline operations, and accelerate access to insights.”
Aperio HALO AP IMS is part of Leica Biosystems’ expanding digital pathology portfolio and reflects the company’s ongoing collaboration with Indica Labs to deliver interoperable solutions for anatomic pathology. The platform is designed to accommodate a wide range of use cases, from image management and collaboration to advanced computational pathology.
In Canada and other applicable regions, Aperio HALO AP IMS is registered as an IVD product and complies with regional regulatory requirements, with availability subject to local approvals. Availability may vary by region.
For In Vitro Diagnostic Use.
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary. For more information, contact us at LeicaBiosystems.com.
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
